Skip to content

US · ELTX · BIOTECHNOLOGY

Elicio Therapeutics, Inc. (ELTX) intrinsic value and stock valuation

$1.45as of 2026-11-21 · Mkt cap 60.82M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Elicio Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values ELTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ELTX’s statements →

Elicio Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02210 elicio.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-39.57M
20122025
Free cash flow
-$-36.97M
20122025
Total equity
$1.64M
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$28.3M
Operating income-$-37.71M-$-44.99M-$-35.74M-$-23.73M-$-39.31M
Net income-$-39.57M-$-51.9M-$-35.2M-$-28.21M-$-26.4M
EPSd-$-2.58M-$-4.25M-$-6.96M-$-9.1M-$-8.25M
Operating cash flow-$-36.95M-$-37.07M-$-32.69M-$-22.18M-$-23.94M
Capital expenditure-$-20K-$-90K-$-70K-$-650K-$-530K
Free cash flow-$-36.97M-$-37.16M-$-32.76M-$-22.83M-$-24.46M
Total assets$25.9M$28.2M$27.2M$22.7M$96.5M
Total debt$14.5M$26M$6.92M$7.48M$4.66M
Net debt-$-4.05M$8.42M-$-5.98M-$-320K-$-84.09M
Total equity$1.64M-$-11.31M$11.4M$8.91M$81.5M
Cash and short-term investments$18.6M$17.6M$12.9M$7.8M$88.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$28.3M
Cost of revenue$1.13M$1.18M$1.17M$1.06M$1.23M
Gross profit-$-1.13M-$-1.18M-$-1.17M-$-1.06M$27.1M
Research and development expenses$24.9M$33.7M$22.7M$17.1M$48.6M
Selling, general and administrative expenses$12.8M$11.3M$11.9M$5.63M$17.8M
Other expenses-$-1.13M-$-1.18M$0.00$0.00$0.00
Operating expenses$36.6M$43.8M$34.6M$22.7M$66.4M
Cost and expenses$37.7M$45M$35.7M$23.7M$67.6M
Interest income$780K$780K$370K$60K$0.00
Interest expense$1.13M$460K$1.06M$3.6M$880K
Depreciation and amortization$1.13M$1.18M$1.17M$1.06M$800K
Ebitda-$-37.31M-$-50.27M-$-32.97M-$-23.55M-$-51.92M
Operating income-$-37.71M-$-44.99M-$-35.74M-$-23.73M-$-39.31M
Total other income/expenses, net-$-1.86M-$-6.91M$550K-$-4.47M-$-15.27M
Income before tax-$-39.57M-$-51.9M-$-35.2M-$-28.21M-$-54.57M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-39.57M-$-51.9M-$-35.2M-$-28.21M-$-26.4M
Weighted average shares outstanding$15.3M$12.2M$5.06M$3.1M$3.2M
Weighted average diluted shares outstanding$15.3M$12.2M$5.06M$3.1M$3.2M
Balance sheet
20252024202320222021
Cash and short-term investments$18.6M$17.6M$12.9M$7.8M$88.8M
Net receivables$0.00$0.00$0.00$0.00$810K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$19.3M$20.7M$16.4M$10.7M$91.3M
Property, plant and equipment, net$5.08M$6.19M$7.28M$8.5M$4.44M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$700K$0.00$620K$720K
Total non-current assets$6.55M$7.49M$10.8M$12M$5.27M
Total assets$25.9M$28.2M$27.2M$22.7M$96.5M
Accounts payable$670K$1.04M$4.37M$2.81M$4.71M
Short-term debt$1.01M$900K$910K$690K$950K
Deferred revenue$0.00$1.17M$0.00$1.44M$2.3M
Total current liabilities$8.11M$11.5M$9.76M$6.87M$11.3M
Long-term debt$13.5M$25.1M$6.01M$6.79M$3.71M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$16.1M$28M$6.02M$6.88M$3.71M
Capital lease obligations$5.11M$5.11M$6.92M$6.79M$3.71M
Total liabilities$24.2M$39.5M$15.8M$13.8M$15M
Common stock$180K$110K$100K$0.00$300K
Retained earnings-$-233.67M-$-194.1M-$-142.2M-$-107.01M-$-215.13M
Accumulated other comprehensive income (loss)-$-130K-$-170K-$-200K$0.00-$-100K
Total equity$1.64M-$-11.31M$11.4M$8.91M$81.5M
Total investments$0.00$700K$0.00$620K$720K
Total debt$14.5M$26M$6.92M$7.48M$4.66M
Net debt-$-4.05M$8.42M-$-5.98M-$-320K-$-84.09M
Cash flow statement
20252024202320222021
Net income-$-39.57M-$-51.9M-$-35.2M-$-28.21M-$-26.4M
Depreciation and amortization$1.13M$1.18M$1.17M$1.06M$250K
Stock-based compensation$2.7M$1.45M$1.18M$580K$620K
Change in working capital-$-3.44M$3.96M-$-60K-$-150K$870K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-370K-$-3.33M$20K$1.12M$30K
Net cash provided by operating activities-$-36.95M-$-37.07M-$-32.69M-$-22.18M-$-23.94M
Investments in property, plant and equipment-$-20K-$-90K-$-70K-$-650K-$-530K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-20K-$-80K-$-30K-$-650K-$-530K
Common stock issued$26.8M$5.63M$7M$80K$100K
Common stock repurchased$0.00$0.00-$-150K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$36.7M$42.3M$38.6M$21.2M$19.4M
Net change in cash-$-230K$5.19M$5.89M-$-80.96M-$-5.07M
Cash at end of period$19.3M$19.5M$14.3M$7.8M$10M
Operating cash flow-$-36.95M-$-37.07M-$-32.69M-$-22.18M-$-23.94M
Capital expenditure-$-20K-$-90K-$-70K-$-650K-$-530K
Free cash flow-$-36.97M-$-37.16M-$-32.76M-$-22.83M-$-24.46M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Elicio Therapeutics, Inc.

        Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

        CEO
        Robert T. Connelly
        Employees
        33
        Beta
        1.78

        Explore

        Frequently asked questions

        What is the intrinsic value of Elicio Therapeutics, Inc. (ELTX)?

        InvestorsCraft does not currently publish an intrinsic value for ELTX. How the IC value is calculated.

        Is ELTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for ELTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.